[Congressional Bills 116th Congress]
[From the U.S. Government Publishing Office]
[H.R. 1614 Introduced in House (IH)]

<DOC>






116th CONGRESS
  1st Session
                                H. R. 1614

    To amend the Controlled Substances Act to establish additional 
  registration requirements for prescribers of opioids, and for other 
                               purposes.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                             March 7, 2019

 Mr. Katko (for himself and Mr. Suozzi) introduced the following bill; 
  which was referred to the Committee on Energy and Commerce, and in 
    addition to the Committee on the Judiciary, for a period to be 
subsequently determined by the Speaker, in each case for consideration 
  of such provisions as fall within the jurisdiction of the committee 
                               concerned

_______________________________________________________________________

                                 A BILL


 
    To amend the Controlled Substances Act to establish additional 
  registration requirements for prescribers of opioids, and for other 
                               purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``John S. McCain Opioid Addiction 
Prevention Act''.

SEC. 2. REGISTRATION REQUIREMENTS FOR PRESCRIBERS.

    Section 303 of the Controlled Substances Act (21 U.S.C. 823) is 
amended by adding at the end the following:
    ``(l)(1) Creating obligations for practitioners, only as described 
herein, the Attorney General shall not register, or renew the 
registration of, a practitioner under subsection (f) who is licensed 
under State law to prescribe controlled substances in schedule II, III, 
or IV, unless the practitioner submits to the Attorney General, for 
each such registration or renewal request, a certification that the 
practitioner, during the applicable registration period, will not 
prescribe any schedule II, III, or IV opioid, other than an opioid 
prescription described in paragraph (3), for the initial treatment of 
acute pain in an amount in excess of the lesser of--
            ``(A) a 7-day supply (for which no refill is available); or
            ``(B) an opioid prescription limit established under State 
        law.
    ``(2) In this subsection, the term `acute pain'--
            ``(A) means pain with abrupt onset and caused by an injury 
        or other process that is not ongoing; and
            ``(B) does not include--
                    ``(i) chronic pain;
                    ``(ii) pain being treated as part of cancer care;
                    ``(iii) hospice or other end-of-life care; or
                    ``(iv) pain being treated as part of palliative 
                care.
    ``(3) An opioid prescription described in this paragraph is a 
prescription--
            ``(A) for a schedule II, III, or IV opioid drug approved by 
        the Food and Drug Administration for an indication for the 
        treatment of addiction; and
            ``(B) that is for the treatment of addiction.''.
                                 <all>